The initial MOA that received the FDA approvals of the Hsp90 inhibitor clinical trials is now called into question, since these inhibitors actually blocked both intracellular and extracellular Hsp90 and extracellular Hsp90α supports tumor formation and metastasis. This evidence concerns the gene HSP90AA1 and neoplasm.